Exploring efficacy and safety of oral Pirfenidone for progressive, non-IPF lung fibrosis (RELIEF) - a randomized, double-blind, placebo-controlled, parallel group, multi-center, phase II trial

BACKGROUND: Pirfenidone is currently approved in the EU for the treatment of mild to moderate idiopathic pulmonary fibrosis (IPF) and offers a beneficial risk-benefit profile. However, there are several other, progressive fibrotic lung diseases, in which conventional anti-inflammatory therapy is not...

Descripción completa

Detalles Bibliográficos
Autores principales: Behr, Jürgen, Neuser, Petra, Prasse, Antje, Kreuter, Michael, Rabe, Klaus, Schade-Brittinger, Carmen, Wagner, Jasmin, Günther, Andreas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5588600/
https://www.ncbi.nlm.nih.gov/pubmed/28877715
http://dx.doi.org/10.1186/s12890-017-0462-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5588600/
https://www.ncbi.nlm.nih.gov/pubmed/28877715
http://dx.doi.org/10.1186/s12890-017-0462-y

Ejemplares similares